Article
Oncology
Jara Palomero, Carla Panisello, Maria Lozano-Rabella, Ricky Tirtakasuma, Judit Diaz-Gomez, Daniela Grases, Helena Pasamar, Laura Arregui, Eduard Dorca Duch, Esther Guerra Fernandez, Ana Vivancos, Carlos E. de Andrea, Ignacio Melero, Jordi Ponce, August Vidal, Josep Maria Piulats, Xavier Matias-Guiu, Alena Gros
Summary: Our study investigates the prevalence, phenotype, specificity and prognostic value of tumor infiltrating lymphocytes (TILs) in endometrial cancer (EC). We found that CD8(+)TILs expressing high levels of PD-1 and CD39 were associated with tumor reactivity and improved patient survival. The co-expression of inhibitory and activation markers on PD-1(hi) CD4(+) T cells was also observed, which accumulated antitumor T cells and correlated with prolonged survival in EC patients.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Oncology
Wei Shi, Mackenzie Fijardo, Jeff P. Bruce, Jie Su, Wei Xu, Rachel Bell, Pierre-Antoine Bissey, Angela B. Y. Hui, John Waldron, Trevor J. Pugh, Kenneth W. Yip, Fei-Fei Liu
Summary: This study reveals the prognostic significance of CD8+ tumor-infiltrating lymphocytes (TILs) in naso-pharyngeal cancer (NPC) and suggests the potential of utilizing CD8+ lymphocytes for immunotherapy.
CLINICAL CANCER RESEARCH
(2022)
Article
Oncology
Qi Zou, Xiaolin Wang, Donglin Ren, Bang Hu, Guannan Tang, Yu Zhang, Meijin Huang, Rish K. Pai, Daniel D. Buchanan, Aung Ko Win, Polly A. Newcomb, William M. Grady, Huichuan Yu, Yanxin Luo
Summary: This study developed a DNA methylation-based signature for CD8+ TILs in colorectal cancer, which showed a strong association with prognosis and immune markers. The QASM assay developed for CD8+ MeTIL markers provided a quantitative and accurate measurement of CD8+ TILs distribution in tumor tissues, indicating potential as a biomarker for therapeutic approaches, including immunotherapy.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Oncology
Veronica Finisguerra, Tereza Dvorakova, Matteo Formenti, Pierre Van Meerbeeck, Lionel Mignion, Bernard Gallez, Benoit J. van den Eynde
Summary: Despite limitations in certain tumor types and patients, immunotherapies have achieved revolutionary success in cancer treatment. However, the efficacy of immunotherapies is dependent on the viability and functionality of tumor antigen-specific CD8 T cells within the immunosuppressive tumor microenvironment, where oxygen levels are often low. This study reveals that the antidiabetic drug metformin can improve CD8 T cell fitness in hypoxia, increasing their proliferation and cytokine production, and enhancing their infiltration and survival in hypoxic tumor areas. This presents a promising strategy to overcome resistance to immunotherapy in hypoxic and immunosuppressive tumors.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Oncology
MacLean S. Hall, Jamie K. Teer, Xiaoqing Yu, Holly Branthoover, Sebastian Snedal, Madeline Rodriguez-Valentin, Luz Nagle, Ellen Scott, Ben Schachner, Patrick Innamarato, Amy M. Hall, Jamie Blauvelt, Carolyn J. Rich, Allison D. Richards, Jake Ceccarelli, T. J. Langer, Sean J. Yoder, Matthew S. Beatty, Cheryl A. Cox, Jane L. Messina, Daniel Abate-Daga, James J. Mule, John E. Mullinax, Amod A. Sarnaik, Shari Pilon-Thomas
Summary: This study highlights the importance of neoantigen-specific CD4(+)T cells within tumor-infiltrating lymphocytes (TILs) as a potent source of tumor-specific effectors. The findings suggest that these CD4(+)T cells play a significant role in antitumor immunity and should be included in future adoptive cell therapy (ACT) protocols to improve treatment efficacy.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Oncology
Qiaoqi Sui, Dingxin Liu, Wu Jiang, Jinghua Tang, Lingheng Kong, Kai Han, Leen Liao, Yuan Li, Qingjian Ou, Binyi Xiao, Guochen Liu, Yihong Ling, Jiewei Chen, Zexian Liu, Zhixiang Zuo, Zhizhong Pan, Penghui Zhou, Jian Zheng, Pei-Rong Ding
Summary: DKK1 suppresses the antitumor immune reaction via the GSK3 beta/E2F1/T-bet axis in CD8+ T cells. Elevated serum DKK1 predicts poor tumor response to PD-1 blockade in dMMR/MSI CRCs, and DKK1 neutralization may restore sensitivity to PD-1 blockade.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Oncology
Jennifer Wilkinson Carlisle, Caroline S. Jansen, Maria Andrea Cardenas, Ewelina Sobierajska, Adriana Moon Reyes, Rachel Greenwald, Luke Del Balzo, Nataliya Prokhnevska, Omer Kucuk, Bradley C. Carthon, Patrick Connor Mullane, Adeboye Osunkoya, Deborah Baumgarten, Fares Hosseinzadeh, Scott Wilkinson, Ross Lake, Adam G. Sowalsky, Yuan Liu, Viraj A. Master, Mehmet A. Bilen, Haydn Kissick
Summary: This study identifies potential immunological biomarkers that can predict therapeutic response in patients with advanced renal cell carcinoma (RCC). Assessing changes in T cells in the peripheral blood and tumor microenvironment, the researchers found that patients with the highest increase in specific activated T cells had the best antitumor immune response and clinical benefit.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Immunology
Andrea Aran, Gonzalo Lazaro, Vicente Marco, Elisa Molina, Ferran Abanco, Vicente Peg, Maria Gion, Laia Garrigos, Jose Perez-Garcia, Javier Cortes, Merce Marti
Summary: Tumor-infiltrating lymphocytes (TILs) have predictive and prognostic value in breast cancer. TCR differences between CD4+ and CD8+ TILs were observed, and a more restricted TCR repertoire with higher similarity was found in CD4+ TILs.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Oncology
Binglin Wang, Yi Wang, Xiaofan Sun, Guoliang Deng, Wei Huang, Xingxin Wu, Yanghong Gu, Zhigang Tian, Zhimin Fan, Qiang Xu, Hongqi Chen, Yang Sun
Summary: This study revealed that CXCR6 is exclusively expressed on intratumoral CD8(+) T cells, which are more immunocompetent and possess stronger antitumor activity. Additionally, CXCR6 may serve as a biomarker for tumor immunotherapy.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Oncology
Takayuki Ohkuri, Akemi Kosaka, Maki Ikeura, Andres M. Salazar, Hideho Okada
Summary: While adoptive transfer of T-cells has been successful for B cell malignancies, developing effective T-cell-based immunotherapy for CNS tumors like glioblastoma remains challenging. Tc17-1 cells, which produce both IL-17 and IFN-gamma, showed promising results in combination with poly-ICLC and peptide vaccine treatment in a preclinical GBM model.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Oncology
Karen Kai-Lin Fang, Jongbok Lee, Ismat Khatri, Yoosu Na, Li Zhang
Summary: The use of allogeneic CAR4-DNTs as adoptive cell therapy for T-cell malignancies is effective. CAR4-DNTs can effectively target T-ALL and PTCL and have superior cytotoxicity compared to empty-vector transduced DNTs.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Oncology
Chester Lai, George Coltart, Andrew Shapanis, Conor Healy, Ahmad Alabdulkareem, Sara Selvendran, Jeffrey Theaker, Matthew Sommerlad, Matthew Rose-Zerilli, Aymen Al-Shamkhani, Eugene Healy
Summary: The study identified a significant presence of CD8+CD103+ TRMs in cutaneous squamous cell carcinomas, with their expression in the tumor being associated with poorer clinical outcomes for patients.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Editorial Material
Oncology
Werner Held, Daniel E. Speiser
Summary: Adoptive cell immunotherapy using in vitro expanded autologous tumor-infiltrating lymphocytes shows potential for durable remission in certain cancers, but complete and long-lasting control of metastatic melanoma requires tumor-specific CD8(+) T cells with stem-cell-like properties.
Article
Immunology
Kaili Liao, Qijun Yang, Yuhan Xu, Yingcheng He, Jingyi Wang, Zimeng Li, Chengfeng Wu, Jialing Hu, Xiaozhong Wang
Summary: This study identified specific marker genes for CD8+ T cell subsets in colon cancer and constructed a prognostic evaluation model. The model was able to predict the prognosis and drug response of patients with colon cancer. The study found that certain genes had high mutation rates in specific risk groups, and patients in the high-risk group had lower drug response rates.
CLINICAL IMMUNOLOGY
(2023)
Article
Oncology
Aubrey S. Smith, Hannah M. Knochelmann, Megan M. Wyatt, Guillermo O. Rangel Rivera, Amalia M. Rivera-Reyes, Connor J. Dwyer, Michael B. Ware, Anna C. Cole, David M. Neskey, Mark P. Rubinstein, Bei Liu, Jessica E. Thaxton, Eric Bartee, Chrystal M. Paulos
Summary: TLR agonists can be repurposed ex vivo to condition T cells, improving immunotherapy and revealing the vital role of B cells in the generation of potent CD8(+) T cell-based therapies.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Editorial Material
Clinical Neurology
Joel R. Martin, Timothy Y. Wang, Daniel Loriaux, Rupen Desai, Maragatha Kuchibhatla, Isaac O. Karikari, Carlos A. Bagley, Oren N. Gottfried
JOURNAL OF CLINICAL NEUROSCIENCE
(2017)
Article
Clinical Neurology
Elizabeth W. Reiser, Rupen Desai, Sarah A. Byrd, Harrison Farber, Deborah Chi, Cary S. Idler, Robert E. Isaacs
Article
Clinical Neurology
S. Harrison Farber, Gautam Nayar, Rupen Desai, Elizabeth W. Reiser, Sarah A. Byrd, Deborah Chi, Cary Idler, Robert E. Isaacs
EUROPEAN SPINE JOURNAL
(2018)
Article
Oncology
Carter M. Suryadevara, Rupen Desai, Melissa L. Abel, Katherine A. Riccione, Kristen A. Batich, Steven H. Shen, Pakawat Chongsathidkiet, Patrick C. Gedeon, Aladine A. Elsamadicy, David J. Snyder, James E. Herndon, Patrick Healy, Gary E. Archer, Bryan D. Choi, Peter E. Fecci, John H. Sampson, Luis Sanchez-Perez
Article
Oncology
Carter M. Suryadevara, Rupen Desai, S. Harrison Farber, Bryan D. Choi, Adam M. Swartz, Steven H. Shen, Patrick C. Gedeon, David J. Snyder, James E. Herndon, Patrick Healy, Elizabeth A. Reap, Gary E. Archer, Peter E. Fecci, John H. Sampson, Luis Sanchez-Perez
CLINICAL CANCER RESEARCH
(2019)
Article
Clinical Neurology
Rupen Desai, Anja Srienc, Robi N. Maamari, Philip L. Custer, David K. Warren, Michael R. Chicoine
Summary: This report discusses a unique application of an orbitofrontal craniotomy for the removal of a foreign object penetrating through the orbit and frontal lobe, as well as postoperative management and antimicrobial therapy. Following successful surgery, the patient remained neurologically intact.
OPERATIVE NEUROSURGERY
(2021)
Meeting Abstract
Hematology
Jennifer A. Foltz, Melissa M. Berrien-Elliott, David A. Russler-Germain, Carly C. Neal, Jennifer Tran, Margery Gang, Pamela Wong, Matthew Mosior, Jeffrey J. Bednarski, Clare Zimmerman, Celia C. Cubitt, Nancy D. Marin, Alice Y. Zhou, Miriam T. Jacobs, Mark Foster, Timothy Schappe, Ethan McClain, Sweta Desai, Patrick Pence, Michelle Becker-Hapak, Lynne Marsala, Obi L. Griffith, Malachi Griffith, Saad M. Khan, Bryan Fisk, Amanda F. Cashen, Allegra A. Petti, Todd A. Fehniger
Article
Cell Biology
Melissa M. Berrien-Elliott, Jennifer A. Foltz, David A. Russler-Germain, Carly C. Neal, Jennifer Tran, Margery Gang, Pamela Wong, Bryan Fisk, Celia C. Cubitt, Nancy D. Marin, Alice Y. Zhou, Miriam T. Jacobs, Mark Foster, Timothy Schappe, Ethan McClain, Samantha Kersting-Schadek, Sweta Desai, Patrick Pence, Michelle Becker-Hapak, Jeremy Eisele, Matthew Mosior, Lynne Marsala, Obi L. Griffith, Malachi Griffith, Saad M. Khan, David H. Spencer, John F. DiPersio, Rizwan Romee, Geoffrey L. Uy, Camille N. Abboud, Armin Ghobadi, Peter Westervelt, Keith Stockerl-Goldstein, Mark A. Schroeder, Fei Wan, Wen-Rong Lie, Patrick Soon-Shiong, Allegra A. Petti, Amanda F. Cashen, Todd A. Fehniger
Summary: In a clinical trial for relapsed/refractory acute myeloid leukemia (AML), same-donor memory-like (ML) NK cell therapy supported by N-803 successfully augmented reduced-intensity conditioning (RIC) haploidentical hematopoietic cell transplantation (HCT). Donor ML NK cells had unique phenotypic and transcriptional profiles and exhibited enhanced ex vivo function compared to conventional NK cells.
SCIENCE TRANSLATIONAL MEDICINE
(2022)
Article
Genetics & Heredity
Anthony Z. Wang, Jay A. Bowman-Kirigin, Rupen Desai, Liang- Kang, Pujan R. Patel, Bhuvic Patel, Saad M. Khan, Diane Bender, M. Caleb Marlin, Jingxian Liu, Joshua W. Osbun, Eric C. Leuthardt, Michael R. Chicoine, Ralph G. Dacey Jr, Gregory J. Zipfel, Albert H. Kim, David G. DeNardo, Allegra A. Petti, Gavin P. Dunn
Summary: This study represents the first comprehensive characterization of both non-tumor-associated human dura and primary meningioma samples using single-cell RNA sequencing. The research reveals a complex immune microenvironment in human dura, which is different from that of meningioma, and describes a diverse landscape of non-immune cells. Significant TCR overlap between matched dura and meningioma samples is shown through T cell receptor sequencing, and copy number variant heterogeneity within meningioma samples is reported.
Article
Oncology
Maximilian O. Schaettler, Rupen Desai, Anthony Z. Wang, Alexandra J. Livingstone, Dale K. Kobayashi, Andrew T. Coxon, Jay A. Bowman-Kirigin, Connor J. Liu, Mao Li, Diane E. Bender, Michael J. White, David M. Kranz, Tanner M. Johanns, Gavin P. Dunn
Summary: Researchers isolated a TCR specific for the Imp3(D81N) neoantigen and generated the MISTIC mouse model. Adoptive cellular therapy using MISTIC T cells showed potential therapeutic efficacy for glioblastoma treatment.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Oncology
Allegra A. Petti, Saad M. Khan, Ziheng Xu, Nichole Helton, Catrina C. Fronick, Robert Fulton, Sai M. Ramakrishnan, Sridhar Nonavinkere Srivatsan, Sharon E. Heath, Peter Westervelt, Jacqueline E. Payton, Matthew J. Walter, Daniel C. Link, John DiPersio, Christopher Miller, Timothy J. Ley
Summary: This study investigates the clonal and transcriptional adaptations in patients with acute myeloid leukemia (AML) after relapse. The researchers collected presentation and relapse samples from six AML cases and performed whole-genome sequencing and single-cell RNA sequencing. The study reveals the coevolution of genetic and transcriptional heterogeneity during AML progression, and identifies a relapse-enriched leukemic cell state with distinct transcriptional properties.
BLOOD CANCER DISCOVERY
(2022)
Article
Biochemistry & Molecular Biology
Saad M. Khan, Fei He, Duolin Wang, Yongbing Chen, Dong Xu
COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL
(2020)
Article
Mathematical & Computational Biology
Saad M. Khan, Jason E. Denney, Michael X. Wang, Dong Xu
QUANTITATIVE BIOLOGY
(2018)